$FATE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in FATE THERAPEUTICS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in FATE THERAPEUTICS INC. Get notifications about new insider transactions in FATE THERAPEUTICS INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 09 2019 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Sell | S | 16.00 | 25,000 | 400,000 | 45,418 | 70.4 K to 45.4 K (-35.50 %) |
| Jan 09 2019 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Buy | M | 2.90 | 12,451 | 36,108 | 70,418 | 58 K to 70.4 K (+21.48 %) |
| Jan 09 2019 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Buy | M | 1.69 | 8,461 | 14,299 | 57,967 | 49.5 K to 58 K (+17.09 %) |
| Jan 09 2019 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Buy | M | 1.69 | 2,080 | 3,515 | 49,506 | 47.4 K to 49.5 K (+4.39 %) |
| Jan 09 2019 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Buy | M | 1.37 | 2,008 | 2,751 | 47,426 | 45.4 K to 47.4 K (+4.42 %) |
| Jan 09 2019 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Option Exercise | A | 16.55 | 135,000 | 2,234,250 | 135,000 | |
| Jan 09 2019 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Grant | A | 0.00 | 45,000 | 0 | 135,591 | 90.6 K to 135.6 K (+49.67 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 323 | 3,958 | 1,823,186 | 1.8 M to 1.8 M (-0.02 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 221 | 2,708 | 1,823,509 | 1.8 M to 1.8 M (-0.01 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 630 | 7,719 | 1,823,730 | 1.8 M to 1.8 M (-0.03 %) |
| Dec 26 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 12.25 | 32,300 | 395,775 | 1,824,360 | 1.9 M to 1.8 M (-1.74 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 240 | 3,351 | 1,856,660 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.19 | 640 | 8,445 | 1,856,900 | 1.9 M to 1.9 M (-0.03 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 180 | 2,513 | 1,857,540 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.17 | 423 | 5,569 | 1,857,720 | 1.9 M to 1.9 M (-0.02 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 454 | 6,337 | 1,858,143 | 1.9 M to 1.9 M (-0.02 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.20 | 1,261 | 16,651 | 1,858,597 | 1.9 M to 1.9 M (-0.07 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.96 | 23,023 | 321,364 | 1,859,858 | 1.9 M to 1.9 M (-1.22 %) |
| Dec 21 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 13.21 | 64,989 | 858,362 | 1,882,881 | 1.9 M to 1.9 M (-3.34 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 172 | 2,868 | 1,947,870 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 118 | 1,967 | 1,948,042 | 1.9 M to 1.9 M (-0.01 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 334 | 5,568 | 1,948,160 | 1.9 M to 1.9 M (-0.02 %) |
| Dec 17 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.67 | 17,164 | 286,160 | 1,948,494 | 2 M to 1.9 M (-0.87 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 4,101 | 68,826 | 1,965,658 | 2 M to 2 M (-0.21 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 2,809 | 47,143 | 1,969,759 | 2 M to 2 M (-0.14 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 7,993 | 134,145 | 1,972,568 | 2 M to 2 M (-0.40 %) |
| Dec 14 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.78 | 410,097 | 6,882,576 | 1,980,561 | 2.4 M to 2 M (-17.15 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 796 | 13,303 | 2,390,658 | 2.4 M to 2.4 M (-0.03 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 546 | 9,125 | 2,391,454 | 2.4 M to 2.4 M (-0.02 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 1,552 | 25,937 | 2,392,000 | 2.4 M to 2.4 M (-0.06 %) |
| Dec 13 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Sell | S | 16.71 | 79,634 | 1,330,820 | 2,393,552 | 2.5 M to 2.4 M (-3.22 %) |
| Sep 27 2018 | FATE | FATE THERAPEUTICS ... | Redmile Group, LLC | Director | Buy | P | 13.50 | 3,703,704 | 50,000,004 | 10,359,666 | 6.7 M to 10.4 M (+55.64 %) |
| Aug 02 2018 | FATE | FATE THERAPEUTICS ... | Redmile Group, LLC | Director | Option Exercise | A | 8.93 | 24,000 | 214,320 | 24,000 | |
| Aug 02 2018 | FATE | FATE THERAPEUTICS ... | Lee Michael Stewart | Director | Option Exercise | A | 8.93 | 24,000 | 214,320 | 24,000 | |
| Jul 20 2018 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | A | 11.03 | 450,000 | 4,963,500 | 450,000 | |
| May 16 2018 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Option Exercise | M | 6.90 | 18,138 | 125,152 | 51,862 | |
| May 16 2018 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Option Exercise | M | 4.89 | 2,916 | 14,259 | 67,084 | |
| May 16 2018 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Buy | M | 6.90 | 18,138 | 125,152 | 64,917 | 46.8 K to 64.9 K (+38.77 %) |
| May 16 2018 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Buy | M | 4.89 | 2,916 | 14,259 | 46,779 | 43.9 K to 46.8 K (+6.65 %) |
| May 04 2018 | FATE | FATE THERAPEUTICS ... | RASTETTER WILLIAM H | Director | Option Exercise | A | 9.78 | 16,000 | 156,480 | 16,000 | |
| May 04 2018 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Option Exercise | A | 9.78 | 16,000 | 156,480 | 16,000 | |
| May 04 2018 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 9.78 | 16,000 | 156,480 | 16,000 | |
| May 04 2018 | FATE | FATE THERAPEUTICS ... | EPSTEIN ROBERT S | Director | Option Exercise | A | 9.78 | 16,000 | 156,480 | 16,000 | |
| May 04 2018 | FATE | FATE THERAPEUTICS ... | Coughlin Timothy P | Director | Option Exercise | A | 9.78 | 16,000 | 156,480 | 16,000 | |
| Jan 17 2018 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | A | 6.55 | 348,000 | 2,279,400 | 348,000 | |
| Jan 17 2018 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Option Exercise | A | 6.55 | 200,160 | 1,311,048 | 200,160 | |
| Jan 17 2018 | FATE | FATE THERAPEUTICS ... | Storgard Chris | Chief Medical Offic ... | Option Exercise | A | 6.55 | 186,000 | 1,218,300 | 186,000 | |
| Jan 17 2018 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Option Exercise | A | 6.55 | 186,000 | 1,218,300 | 186,000 | |
| Jan 17 2018 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Option Exercise | A | 6.55 | 186,000 | 1,218,300 | 186,000 | |
| Oct 17 2017 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Sell | S | 4.07 | 800 | 3,256 | 124,881 | 125.7 K to 124.9 K (-0.64 %) |
| Oct 17 2017 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Sell | S | 3.87 | 16,368 | 63,344 | 125,681 | 142 K to 125.7 K (-11.52 %) |
| Oct 17 2017 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Sell | S | 4.10 | 500 | 2,050 | 45,418 | 45.9 K to 45.4 K (-1.09 %) |
| Oct 17 2017 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Sell | S | 3.83 | 7,591 | 29,074 | 45,918 | 53.5 K to 45.9 K (-14.19 %) |
| Oct 17 2017 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Sell | S | 4.08 | 700 | 2,856 | 90,591 | 91.3 K to 90.6 K (-0.77 %) |
| Oct 17 2017 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Sell | S | 3.86 | 12,525 | 48,347 | 91,291 | 103.8 K to 91.3 K (-12.06 %) |
| May 04 2017 | FATE | FATE THERAPEUTICS ... | RASTETTER WILLIAM H | Director | Option Exercise | A | 4.73 | 25,000 | 118,250 | 25,000 | |
| May 04 2017 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Option Exercise | A | 4.73 | 25,000 | 118,250 | 25,000 | |
| May 04 2017 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 4.73 | 25,000 | 118,250 | 25,000 | |
| May 04 2017 | FATE | FATE THERAPEUTICS ... | EPSTEIN ROBERT S | Director | Option Exercise | A | 4.73 | 25,000 | 118,250 | 25,000 | |
| May 04 2017 | FATE | FATE THERAPEUTICS ... | Enyedy Mark J | Director | Option Exercise | A | 4.73 | 25,000 | 118,250 | 25,000 | |
| May 04 2017 | FATE | FATE THERAPEUTICS ... | Coughlin Timothy P | Director | Option Exercise | A | 4.73 | 25,000 | 118,250 | 25,000 | |
| Jan 06 2017 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | A | 2.73 | 250,000 | 682,500 | 250,000 | |
| Jan 06 2017 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Option Exercise | A | 2.73 | 150,000 | 409,500 | 150,000 | |
| Jan 06 2017 | FATE | FATE THERAPEUTICS ... | Storgard Chris | Chief Medical Offic ... | Option Exercise | A | 2.73 | 150,000 | 409,500 | 150,000 | |
| Jan 06 2017 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Option Exercise | A | 2.73 | 150,000 | 409,500 | 150,000 | |
| Nov 28 2016 | FATE | FATE THERAPEUTICS ... | Storgard Chris | Chief Medical Offic ... | Buy | P | 2.66 | 37,593 | 99,997 | 37,593 | 0 to 37.6 K |
| Nov 28 2016 | FATE | FATE THERAPEUTICS ... | RASTETTER WILLIAM H | Director | Buy | P | 2.66 | 375,939 | 999,998 | 459,272 | 83.3 K to 459.3 K (+451.13 %) |
| Nov 28 2016 | FATE | FATE THERAPEUTICS ... | Coughlin Timothy P | Director | Buy | P | 2.66 | 56,390 | 149,997 | 56,390 | 0 to 56.4 K |
| Aug 24 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | M | 1.37 | 2,570 | 3,521 | 0 | |
| Aug 24 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Buy | M | 1.37 | 2,570 | 3,521 | 142,049 | 139.5 K to 142 K (+1.84 %) |
| May 18 2016 | FATE | FATE THERAPEUTICS ... | Storgard Chris | Chief Medical Offic ... | Option Exercise | A | 1.54 | 200,000 | 308,000 | 200,000 | |
| May 18 2016 | FATE | FATE THERAPEUTICS ... | Storgard Chris | Chief Medical Offic ... | Grant | A | 0.00 | 9,090 | 0 | 9,090 | 0 to 9.1 K |
| May 13 2016 | FATE | FATE THERAPEUTICS ... | Enyedy Mark J | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
| May 13 2016 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
| May 13 2016 | FATE | FATE THERAPEUTICS ... | RASTETTER WILLIAM H | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
| May 13 2016 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
| May 13 2016 | FATE | FATE THERAPEUTICS ... | EPSTEIN ROBERT S | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
| May 13 2016 | FATE | FATE THERAPEUTICS ... | Coughlin Timothy P | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
| Jan 20 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | M | 1.63 | 3,702 | 6,034 | 27,935 | |
| Jan 20 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | M | 1.37 | 3,798 | 5,203 | 2,570 | |
| Jan 20 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Buy | M | 1.63 | 3,702 | 6,034 | 139,479 | 135.8 K to 139.5 K (+2.73 %) |
| Jan 20 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Buy | M | 1.37 | 3,798 | 5,203 | 135,777 | 132 K to 135.8 K (+2.88 %) |
| Jan 14 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | A | 2.70 | 110,400 | 298,080 | 110,400 | |
| Jan 14 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Option Exercise | A | 2.70 | 189,600 | 511,920 | 189,600 | |
| Jan 14 2016 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | President and CEO | Grant | A | 0.00 | 10,956 | 0 | 131,979 | 121 K to 132 K (+9.05 %) |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Option Exercise | A | 2.90 | 135,600 | 393,240 | 135,600 | |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Grant | A | 0.00 | 6,633 | 0 | 53,509 | 46.9 K to 53.5 K (+14.15 %) |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Option Exercise | A | 2.90 | 148,800 | 431,520 | 148,800 | |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Grant | A | 0.00 | 9,388 | 0 | 103,816 | 94.4 K to 103.8 K (+9.94 %) |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Option Exercise | A | 2.90 | 148,800 | 431,520 | 148,800 | |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Grant | A | 0.00 | 3,863 | 0 | 43,863 | 40 K to 43.9 K (+9.66 %) |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | FATE THERAPEUTICS INC | General Counsel and ... | Option Exercise | A | 2.90 | 135,600 | 393,240 | 135,600 | |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | FATE THERAPEUTICS INC | General Counsel and ... | Grant | A | 0.00 | 6,633 | 0 | 53,509 | 46.9 K to 53.5 K (+14.15 %) |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | FATE THERAPEUTICS INC | Chief Scientific Of ... | Option Exercise | A | 2.90 | 148,800 | 431,520 | 148,800 | |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | FATE THERAPEUTICS INC | Chief Scientific Of ... | Grant | A | 0.00 | 9,388 | 0 | 103,816 | 94.4 K to 103.8 K (+9.94 %) |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | FATE THERAPEUTICS INC | Chief Development O ... | Option Exercise | A | 2.90 | 148,800 | 431,520 | 148,800 | |
| Jan 12 2016 | FATE | FATE THERAPEUTICS ... | FATE THERAPEUTICS INC | Chief Development O ... | Grant | A | 0.00 | 3,863 | 0 | 43,863 | 40 K to 43.9 K (+9.66 %) |
| Oct 16 2015 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Scientific Of ... | Grant | A | 0.00 | 66,000 | 0 | 94,428 | 28.4 K to 94.4 K (+232.17 %) |
| Oct 16 2015 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | CFO & Chief Operati ... | Grant | A | 0.00 | 86,250 | 0 | 121,023 | 34.8 K to 121 K (+248.04 %) |
| Oct 16 2015 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Option Exercise | A | 4.89 | 70,000 | 342,300 | 70,000 | |
| Oct 16 2015 | FATE | FATE THERAPEUTICS ... | ABBOT STEWART | Chief Development O ... | Grant | A | 0.00 | 40,000 | 0 | 40,000 | 0 to 40 K |
| Oct 16 2015 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Option Exercise | A | 4.89 | 50,000 | 244,500 | 50,000 | |
| Oct 16 2015 | FATE | FATE THERAPEUTICS ... | TAHL CINDY | General Counsel and ... | Grant | A | 0.00 | 40,000 | 0 | 46,876 | 6.9 K to 46.9 K (+581.73 %) |
| May 15 2015 | FATE | FATE THERAPEUTICS ... | EPSTEIN ROBERT S | Director | Option Exercise | A | 7.08 | 10,000 | 70,800 | 10,000 | |
| May 15 2015 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 7.08 | 10,000 | 70,800 | 10,000 | |
| May 15 2015 | FATE | FATE THERAPEUTICS ... | RASTETTER WILLIAM H | Director | Option Exercise | A | 7.08 | 10,000 | 70,800 | 10,000 | |
| May 15 2015 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Option Exercise | A | 7.08 | 10,000 | 70,800 | 10,000 | |
| May 15 2015 | FATE | FATE THERAPEUTICS ... | Enyedy Mark J | Director | Option Exercise | A | 7.08 | 10,000 | 70,800 | 10,000 | |
| May 15 2015 | FATE | FATE THERAPEUTICS ... | Coughlin Timothy P | Director | Option Exercise | A | 7.08 | 10,000 | 70,800 | 10,000 | |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | See Remarks | Option Exercise | M | 1.63 | 2,936 | 4,786 | 31,637 | |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | See Remarks | Option Exercise | M | 1.37 | 5,064 | 6,938 | 6,368 | |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | See Remarks | Buy | M | 1.63 | 2,936 | 4,786 | 34,773 | 31.8 K to 34.8 K (+9.22 %) |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | See Remarks | Buy | M | 1.37 | 5,064 | 6,938 | 31,837 | 26.8 K to 31.8 K (+18.91 %) |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Weyer Christian | See Remarks | Option Exercise | M | 1.37 | 25,000 | 34,250 | 258,040 | |
| Apr 14 2015 | FATE | FATE THERAPEUTICS ... | Weyer Christian | See Remarks | Buy | M | 1.37 | 25,000 | 34,250 | 30,429 | 5.4 K to 30.4 K (+460.49 %) |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | A | 4.84 | 70,000 | 338,450 | 70,000 | |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Grant | A | 0.00 | 2,466 | 0 | 6,505 | 4 K to 6.5 K (+61.05 %) |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Multani Pratik S | Chief Medical Offic ... | Option Exercise | A | 4.84 | 70,000 | 338,450 | 70,000 | |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Multani Pratik S | Chief Medical Offic ... | Grant | A | 0.00 | 3,024 | 0 | 3,024 | 0 to 3 K |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | See remarks | Option Exercise | A | 4.84 | 70,000 | 338,450 | 70,000 | |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Wolchko J Scott | See remarks | Grant | A | 0.00 | 2,885 | 0 | 26,773 | 23.9 K to 26.8 K (+12.08 %) |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Research Offi ... | Option Exercise | A | 4.84 | 70,000 | 338,450 | 70,000 | |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Shoemaker Daniel D | Chief Research Offi ... | Grant | A | 0.00 | 2,466 | 0 | 28,428 | 26 K to 28.4 K (+9.50 %) |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Weyer Christian | See remarks | Option Exercise | A | 4.84 | 100,000 | 483,500 | 100,000 | |
| Jan 07 2015 | FATE | FATE THERAPEUTICS ... | Weyer Christian | See remarks | Grant | A | 0.00 | 5,429 | 0 | 5,429 | 0 to 5.4 K |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.63 | 1,100 | 1,793 | 24,200 | |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.37 | 422 | 578 | 19,450 | |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.63 | 3,949 | 6,437 | 23,891 | |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.63 | 1,017 | 1,658 | 27,840 | |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Sell | S | 7.00 | 5,471 | 38,297 | 4,039 | 9.5 K to 4 K (-57.53 %) |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Buy | M | 1.63 | 1,100 | 1,793 | 9,510 | 8.4 K to 9.5 K (+13.08 %) |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Buy | M | 1.37 | 422 | 578 | 8,410 | 8 K to 8.4 K (+5.28 %) |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Buy | M | 1.63 | 3,949 | 6,437 | 7,988 | 4 K to 8 K (+97.77 %) |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Sell | S | 7.00 | 1,017 | 7,119 | 4,039 | 5.1 K to 4 K (-20.11 %) |
| Jun 12 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Buy | M | 1.63 | 1,017 | 1,658 | 5,056 | 4 K to 5.1 K (+25.18 %) |
| Jun 11 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.63 | 699 | 1,139 | 28,857 | |
| Jun 11 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.63 | 1,260 | 2,054 | 29,556 | |
| Jun 11 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Sell | S | 7.00 | 1,350 | 9,450 | 4,039 | 5.4 K to 4 K (-25.05 %) |
| Jun 11 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Buy | M | 1.63 | 699 | 1,139 | 5,389 | 4.7 K to 5.4 K (+14.90 %) |
| Jun 11 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Sell | S | 7.00 | 1,955 | 13,685 | 4,690 | 6.6 K to 4.7 K (-29.42 %) |
| Jun 11 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Buy | M | 1.63 | 1,260 | 2,054 | 6,645 | 5.4 K to 6.6 K (+23.40 %) |
| Jun 10 2014 | FATE | FATE THERAPEUTICS ... | Nashat Amir | Director | Option Exercise | A | 6.71 | 10,000 | 67,100 | 10,000 | |
| Jun 09 2014 | FATE | FATE THERAPEUTICS ... | RASTETTER WILLIAM H | Director | Option Exercise | A | 6.71 | 10,000 | 67,100 | 10,000 | |
| Jun 09 2014 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 6.71 | 10,000 | 67,100 | 10,000 | |
| Jun 09 2014 | FATE | FATE THERAPEUTICS ... | EPSTEIN ROBERT S | Director | Option Exercise | A | 6.71 | 10,000 | 67,100 | 10,000 | |
| Jun 09 2014 | FATE | FATE THERAPEUTICS ... | Enyedy Mark J | Director | Option Exercise | A | 6.71 | 10,000 | 67,100 | 10,000 | |
| Jun 09 2014 | FATE | FATE THERAPEUTICS ... | Coughlin Timothy P | Director | Option Exercise | A | 6.71 | 10,000 | 67,100 | 10,000 | |
| May 05 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.37 | 422 | 578 | 19,872 | |
| May 05 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.63 | 1,100 | 1,793 | 25,300 | |
| May 05 2014 | FATE | FATE THERAPEUTICS ... | Flynn Peter D | See remarks | Option Exercise | M | 1.63 | 6,925 | 11,288 | 30,816 |